 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
About Us
Our objective is to develop methods to treat Calcifying Nanoparticles (CNPs), and by so doing find more effective approaches to the diseases associated with them.
Pharmaceutical Drug Discovery
Our drug discovery and development efforts focus on new and existing compounds that effectively inhibit, destroy or neutralize CNPs.
We are narrowly focused on new combinations of well-known drugs that have been shown to eradicate CNPs.
Our business strategy is to develop and license compounds to address unmet needs of patients in the cardiovascular and urological disease markets.
Diagnostics
Our diagnostics division develops in vitro diagnostic products and laboratory services that are used worldwide.
In Vitro Diagnostics Kits and ReagentsWe offer IVD kits and reagents for detection of Calcifying Nanoparticles. Clinical Laboratory ServicesWe provide specialized clinical laboratory testing services to clinicians, hospitals, and laboratories. We specialize in advanced technologies for detecting and characterizing Calcifying Nanoparticles in human samples. Nanobac OY Clinical Laboratory in Finland is fully accredited by government regulatory agencies. BioAnalytical ServicesWe work with partners to develop methods for detecting and eliminating CNPs from raw materials or production substrates. Our contamination control program focuses on decontaminating host cell lines, animal and human derived materials, raw materials, diagnostic procedures and downstream processes. |
Nanobac Pharmaceuticals, Inc.
3000 Bayport Drive, Suite 910
Tampa, Florida 33607
Ph. (813) 865-1125
Email us at:
